São Paulo, 19 December 2024 – MGI Tech Co., Ltd. (“MGI”), a company committed to building core tools and technologies that drive innovation in life science, has recently partnered with Sabin Group, one of the largest diagnostic laboratories in Brazil, to improve health detection through genetic sequencing technology. The collaboration aims to expand the porfolio of exams and enlarge the access of Brazilians to innovative genomics tests offered by Sabin.

(Click the picture to watch the video) 

Sabin Group has been operating in fifteen states of Brazil for 40 years. With thousands of employees, Sabin is now serving more than 7 million customers annually, offering a wide range of clinical analysis, diagnostic imaging, vaccination and examination services.

The partnership between MGI and Sabin is a fundamental step towards the development of personalized medicine in Brazil. By expanding access to advanced genetic sequencing technologies, it is possible to provide more accurate diagnoses and personalize treatments according to each patient’s genetic profile. In addition to improving clinical outcomes, it also promotes a more preventive and efficient approach to healthcare, which can transform medical practice in the country.

“The combination of our cutting-edge technology with Sabin’s vast network and expertise will create a unique synergy that can transform the Brazilian healthcare system. Sabin has a strong and consolidated presence in the country and, by incorporating our genetic sequencing solutions, we can offer more accurate and accessible diagnostics to a broad patient base. This partnership has the potential to raise the standard of care and promote more personalized and efficient medicine in the country,” Carlos Carpio, Senior Commercial Director for MGI Latin America and General Manager for Brazil, explains.

“The implementation of MGI’s sequencing technology at Sabin has significantly advanced our genomic operations. With expanded sequencing capacity and the ability to generate large volumes of high-quality data, we can now perform more comprehensive and precise analyses, enhancing diagnostics and driving the evolution of personalized medicine. This partnership has also seamlessly integrated into our laboratory environment, providing innovative solutions that boost efficiency and support mutual growth. The outcomes are both reliable and high-quality, underscoring our commitment to delivering the best care to our patients while leveraging cutting-edge advancements in genomics”, says Rafael Jácomo,Technical Director.

The partnership will therefore allow cutting-edge genomic tests to be more widely available. By identifying genetic predispositions and performing more accurate diagnoses, patients will be able to adhere to more effective and personalized treatments, generating a positive impact on public health and reducing costs in healthcare systems.

Sabin has implemented the DNBSEQ-G400 genomic sequencer, which enables large- and medium-scale sequencing, and the MGISP-100, an automated library preparation system developed by MGI for high-throughput DNA sequencing. The implementation of the DNBSEQ-G400 has already led to a 78% increase in the number of genomic tests performed, significantly enhancing Sabin's capacity to deliver advanced diagnostics to patients. With the automation provided by the MGISP-100, which processes samples in batches, eliminates repetitive processing procedures for operators, increases the stability of library preparation, reduces total costs, and enhances laboratory efficiency, the expectation is that this growth will be further amplified, enabling even greater advancements in personalized medicine.

Access to advanced medical technologies is often limited due to high costs, so partnerships like this one between MGI and Sabin represent a major step forward by enabling Brazilians to access genomic testing and allowing more people to benefit from the latest advances in precision medicine.

In April of this year, MGI inaugurated the Customer Experience Center (CEC) in Brazil to strengthen genomic sequencing infrastructure and scientific development in the country.

“Genetic sequencing is essential when we talk about precision medicine. With the advancement of new technologies, personalized medicine is already a reality that will further boost the development of healthcare in the country in the upcoming years, offering patients a better quality of life,” Carlos Carpio concludes.  

About MGI 

MGI Tech Co., Ltd.  (or its subsidiaries, together referred to MGI), is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. 

Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit https://en.mgi-tech.com/, Linkedin, X, and Youtube.  

About Sabin  

Sabin Group | With 40 years of experience, the Sabin Group is a reference in health, highlighted in

people management and female leadership, dedicated to the best sustainable practices and active in communities, the Sabin Group was born in Brasília (DF), the result of courage and determination by two entrepreneurs, Janete Vaz and Sandra Soares Costa, in 1984. Today it has 7,000 employees united by the purpose of inspiring people to take care of people.  The group is also present in 14 states and the Federal District offering health services with excellence, innovation and socio-environmental responsibility in 78 cities where it is present with 358 units distributed from north to south of the country.   

The Sabin Group's health ecosystem integrates a business portfolio that includes clinical analysis, imaging diagnostics, pathological anatomy, genomics, immunization and executive check-up.  In addition, it also includes primary care services contributing to the health management of population groups through programs and lines of coordinated care, by Amparo Saúde and an integrated health services platform - Rita Saúde - a digital solution that has several partners such as pharmacies, doctors and other professionals, promoting access to healthcare with quality and efficiency.